Al18F-NOTA-FAPI-04 PET imaging in cancer, heart disease and autoimmune thyroid disease
Tests Al18F-NOTA-FAPI scans in adults with tumors, heart or immune conditions.
Plain-language title generated from the registry record
Registry title: Clinical Application of Al18F-NOTA-FAPI-04 PET/CT or PET/MRI Imaging in Malignant Tumor,Cardiovascular or Immune Disease
Key facts
- Where
- Beijing, ChinaSee the site
- Phase
- Phase 1/2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who had a recent health check-up with no major disease found. It studies a PET scan (Al18F-NOTA-FAPI) in tumor, heart or immune disease.
- Age
- 18 to 88 years
- Sex
- All sexes can join.
- Earlier treatment
- People who had a CT scan within 3 months or a PET/CT within 1 month cannot join.
Main reasons for not taking part
- Had a CT or PET/CT scan within the last 3 months or 1 month, as set by the record
- Frequent radiation exposure for clinical needs
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 88 years old?
Source: NCT07400224, who can take part
Where in China
- Peking Union Medical College HospitalBeijing, ChinaContact: Peking Union Medical College HospitalTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Peking Union Medical College Hospital
- Trial code
- NCT07400224
- Record updated
- 10 February 2026
- Original description
This prospective, single-center study investigates the biodistribution, dosimetry, safety, diagnostic performance of Al18F-NOTA-FAPI PET imaging in patients with malignant tumor,cardiovascular or immune disease. And evaluates the potential of Al18F-NOTA-FAPI PET imaging in Clinical treatment strategy guidance.Read full original descriptionShow less
Clinical Application of Al18F-NOTA-FAPI-04 PET/CT or PET/MRI Imaging in Malignant Tumor,Cardiovascular or Immune Disease
This prospective, single-center study investigates the biodistribution, dosimetry, safety, diagnostic performance of Al18F-NOTA-FAPI PET imaging in patients with malignant tumor,cardiovascular or immune disease. And evaluates the potential of Al18F-NOTA-FAPI PET imaging in Clinical treatment strategy guidance.
Inclusion: a. Age 18 years old or above, gender not restricted. b. Have undergone a health check-up within the last 3 months (at least completed chest X-ray / chest CT and abdominal B-ultrasound and other examinations), and no major diseases were found.
Exclusion: As this study involves certain radiation exposure, patients who have had frequent radiation exposure due to clinical needs (those who have undergone a CT or PET/CT examination once within 3 months or 1 month respectively) are not included in the study.